Literature DB >> 29935101

The analysis of myotonia congenita mutations discloses functional clusters of amino acids within the CBS2 domain and the C-terminal peptide of the ClC-1 channel.

Concetta Altamura1, Sabrina Lucchiari2,3, Dalila Sahbani1, Gianna Ulzi2,3, Giacomo P Comi2,3, Paola D'Ambrosio4, Roberta Petillo4, Luisa Politano4, Liliana Vercelli5, Tiziana Mongini5, Maria Teresa Dotti6, Rosanna Cardani7, Giovanni Meola8, Mauro Lo Monaco9,10, Emma Matthews11, Michael G Hanna11, Maria Rosaria Carratù12, Diana Conte1, Paola Imbrici1, Jean-François Desaphy12.   

Abstract

Myotonia congenita (MC) is a skeletal-muscle hyperexcitability disorder caused by loss-of-function mutations in the ClC-1 chloride channel. Mutations are scattered over the entire sequence of the channel protein, with more than 30 mutations located in the poorly characterized cytosolic C-terminal domain. In this study, we characterized, through patch clamp, seven ClC-1 mutations identified in patients affected by MC of various severities and located in the C-terminal region. The p.Val829Met, p.Thr832Ile, p.Val851Met, p.Gly859Val, and p.Leu861Pro mutations reside in the CBS2 domain, while p.Pro883Thr and p.Val947Glu are in the C-terminal peptide. We showed that the functional properties of mutant channels correlated with the clinical phenotypes of affected individuals. In addition, we defined clusters of ClC-1 mutations within CBS2 and C-terminal peptide subdomains that share the same functional defect: mutations between 829 and 835 residues and in residue 883 induced an alteration of voltage dependence, mutations between 851 and 859 residues, and in residue 947 induced a reduction of chloride currents, whereas mutations on 861 residue showed no obvious change in ClC-1 function. This study improves our understanding of the mechanisms underlying MC, sheds light on the role of the C-terminal region in ClC-1 function, and provides information to develop new antimyotonic drugs.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  C-terminal; ClC-1; myotonia congenita; patch clamp

Mesh:

Substances:

Year:  2018        PMID: 29935101     DOI: 10.1002/humu.23581

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  5 in total

1.  Translating genetic and functional data into clinical practice: a series of 223 families with myotonia.

Authors:  Karen Suetterlin; Emma Matthews; Richa Sud; Samuel McCall; Doreen Fialho; James Burge; Dipa Jayaseelan; Andrea Haworth; Mary G Sweeney; Dimitri M Kullmann; Stephanie Schorge; Michael G Hanna; Roope Männikkö
Journal:  Brain       Date:  2022-04-18       Impact factor: 15.255

2.  Targeted Therapies for Skeletal Muscle Ion Channelopathies: Systematic Review and Steps Towards Precision Medicine.

Authors:  Jean-François Desaphy; Concetta Altamura; Savine Vicart; Bertrand Fontaine
Journal:  J Neuromuscul Dis       Date:  2021

Review 3.  Clinical and molecular characteristics of myotonia congenita in China: Case series and a literature review.

Authors:  Yifan Li; Mao Li; Zhenfu Wang; Fei Yang; Hongfen Wang; Xiujuan Bai; Bo Sun; Siyu Chen; Xusheng Huang
Journal:  Channels (Austin)       Date:  2022-12       Impact factor: 2.581

Review 4.  Therapeutic Targets in Amyotrophic Lateral Sclerosis: Focus on Ion Channels and Skeletal Muscle.

Authors:  Nancy Tarantino; Ileana Canfora; Giulia Maria Camerino; Sabata Pierno
Journal:  Cells       Date:  2022-01-25       Impact factor: 6.600

5.  Chaperone activity of niflumic acid on ClC-1 chloride channel mutants causing myotonia congenita.

Authors:  Concetta Altamura; Elena Conte; Carmen Campanale; Paola Laghetti; Ilaria Saltarella; Giulia Maria Camerino; Paola Imbrici; Jean-François Desaphy
Journal:  Front Pharmacol       Date:  2022-08-11       Impact factor: 5.988

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.